We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| bluebird bio Inc | NASDAQ:BLUE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0337 | -3.65% | 0.8897 | 0.884 | 0.8891 | 0.9383 | 0.88 | 0.9234 | 4,131,637 | 16:03:10 |
From Apr 2022 to Apr 2024
By Kathryn Hardison
The U.S. Food and Drug Administration approved bluebird bio Inc.'s cell-based gene therapy on Wednesday called Zynteglo.
The therapy is designed for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusion. The FDA said Zynteglo is the first cell-based gene therapy for the blood disorder.
Zynteglo is a one-time gene therapy product administered as a single dose. The agency said that each dose of Zynteglo is a customized treatment created using the patient's own cells that are genetically modified to produce functional beta-globin.
Zynteglo's safety and effectiveness were established in two multicenter clinical studies that included both adult and pediatric patients. The most common reactions associated with Zynteglo included reduced platelet and other blood cell levels, as well as symptoms like vomiting, alopecia, cough, headache, rash and more.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
August 17, 2022 14:15 ET (18:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year bluebird bio Chart |
1 Month bluebird bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
